

### **Remarks**

Prior to entry of this Amendment, claims 1, 2, 6-10, 13, 15, 16, 18-24, 26, 27, 29-34, 36, 38, and 41-46 were pending in the application. By this amendment, claims 1, 2, 6-10, 13, 15, 16, 18, 28, and 29 are canceled without prejudice as to future prosecution, and claims 19, 21, 30, 43, and 45 are amended. New claim 49 (based on language in original claim 18) is added. Support for the amendments can be found throughout the specification and the original claims; where appropriate, specific support is discussed below. No new matter has been added by these amendments.

Applicants expressly reserve the right to pursue subject matter removed from consideration by this amendment in a later-filed application. After entry of this amendment, **claims 19-24, 26, 30-34, 36, 38, 41-46 and 49 are pending** and believed to be in condition for allowance.

#### *Allowed and Allowable Claims*

Applicants thank the Examiner for indicating that claims 34, 36, 38, 41, 42, 44, and 46 are allowed. None of these claims are amended by this filing, and so they remain allowed.

Applicants also thank the Examiner for indicating that claims 15, 20, 22-24, 26, and 30-33 would be allowable if rewritten in independent form including all the limitations of the base claim and any intervening claims. Claim 15 has been canceled herewith without prejudice. As suggested, the remaining claims now include the limitations of claim(s) from which they previously depended. In particular, text from claim 16 has been incorporated into claim 19, from which depends claim 20 (and further dependent claims). Claims 20, 22-24, 26, and 30-33 are therefore believed to be allowable, and notification of their allowance is respectfully requested.

#### *Rejection under 35 U.S.C. §112, 1<sup>st</sup> paragraph:*

Claim 21 is rejected for allegedly failing to satisfy the enablement requirement with regard to use of the term “diaphorase”. In the interests of moving prosecution along, this term has been removed from claim 21. Withdrawal of this rejection is respectfully requested.

*Rejections under 35 U.S.C. §112, 2<sup>nd</sup> paragraph:*

Claims 8, 13, 19, 43, and 45 are each rejected as allegedly indefinite for failing to point out and distinctly claim the subject matter Applicants' regard as the invention. Of these claims, claims 8 and 13 are canceled herewith, rendering their rejection moot.

Claim 19 is rejected as ambiguous and unclear because "the molecule remains reduced." Applicants have amended the language of claims 19 herewith to address this rejection, and believe that the now-pending claim is clear and unambiguous. Withdrawal of this rejection is respectfully requested.

Claim 43 is rejected as ambiguous and unclear for use of the phrase "releasing the immunocomplex" without an indication of what it is to be released from. In the interests of moving prosecution along, this phrase has been removed from claim 43. Withdrawal of this rejection is respectfully requested.

Claim 45 is rejected as ambiguous and unclear for use of the phrase "high throughput screening", in that this is allegedly not a "detecting" step. In the interests of moving prosecution along, this phrase has been removed from claim 45. Withdrawal of this rejection is respectfully requested.

*Rejections under 35 U.S.C. §102(b)*

Claims 1, 2, 6-10, 13, 16, 18, and 29 have been rejected as allegedly anticipated by Suhr *et al.*, 1990. Without addressing or conceding to the accuracy of this rejection, Applicants have cancelled these rejected claims in order to advance prosecution in this case. This rejection is moot as to the now-pending claims, and Applicants request its withdrawal.

**Conclusion**

Based on the foregoing amendments and comments, the pending claims are in condition for allowance and notification to this effect is requested. If any questions remain before the claims can be allowed, the Examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Tanya M. Harding/  
Tanya M. Harding, Ph.D.  
Registration No. 42,630